ArticleRadiation oncology (London, England)2025
A nomogram integrating clinical stage and pre-EBV DNA to identify the cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07088861 (Validation and Analysis of the 9th Edition AJCC/UICC Staging System for Nasopharyngeal Carcinoma in Non-High-Incidence Areas in China - A Multicentre Retrospective Clinical Study), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validation and Analysis of the 9th Edition AJCC/UICC Staging System for Nasopharyngeal Carcinoma in Non-High-Incidence Areas in China - A Multicentre Retrospective Clinical Study
Who cites it
2 citing papers in PubMed.
- Prognostic significance of immune-inflammatory and nutritional indicators in locoregionally advanced nasopharyngeal carcinoma.Frontiers in immunology · 2026Article
- MRI-based model for individualized prediction of skull bone destruction and EBV DNA-related risk stratification in nasopharyngeal carcinoma patients.BMC medical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis research focused on determining the optimal cycles of induction chemotherapy (IC) in high-risk locoregionally advanced nasopharyngeal carcinoma (LA-NPC).
methodsThe retrospective analysis was conducted on 885 patients. Potential bias was minimized by propensity score matching (PSM). Overall survival (OS) served as the primary endpoint. Survival outcomes were analyzed using Kaplan-Meier curves, with statistical comparisons performed via the log-rank test. Prognostic determinants were identified through multivariate cox regression analysis. A nomogram model was constructed to quantify individualized prognosis.
resultsPatients were divided into 2/3-cycle (IC = 2/3) and 4-cycle IC (IC = 4) groups. After PSM, 446 patients remained and were categorized into distinct risk groups according to independent predictors, including clinical stage and pre-treatment Epstein-Barr virus DNA (pre-EBV DNA). For the high-risk cohort (stage IVa with pre-EBV DNA ≥ 4000 copies/mL), the IC = 4 regimen showed higher 5-year OS (70.4% vs. 54.7%, P = 0.036) than the IC = 2/3 regimen. In the low- and middle-risk cohorts, the IC = 2/3 regimen exhibited OS comparable to the IC = 4 regimen. The established nomogram model demonstrated superior prognostic power compared to individual factors. Given the adverse effects, the IC = 4 regimen was associated with significantly higher rates of grade 3-4 neutropenia (24.6% vs. 15.5%, P = 0.017) and thrombocytopenia (8.0% vs. 3.7%, P = 0.049) compared to the IC = 2/3 regimen.
conclusionThe developed nomogram offers personalized guidance on selecting individual IC cycles for LA-NPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.